In this review:
This review discusses the use of IV trastuzumab emtansine [Kadcyla®], a HER2-targeted antibodydrug
conjugate, registered for use in New Zealand as a single agent for the treatment of HER2-positive metastatic breast cancer (please see data sheet for complete indication statement).1 Trastuzumab emtansine is the first antibody-drug conjugate approved for use in this setting and has proven to be effective and generally well tolerated.2 Trastuzumab emtansine is fully funded for patients with HER2- positive breast cancer who meet pre-defined criteria from 1 December 2019.
Please login below to download this issue (PDF)